drugset / Trial / NCT07130175

Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)

NCT07130175 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, randomized, controlled trial to investigate the efficacy of radiofrequency catheter ablation (RFCA) combined with guideline-directed medical therapy (GDMT) compared to GDMT alone in patients with polymorphic ventricular tachycardia (PMVT) and coexisting heart failure (HF). The study aims to evaluate whether the addition of RFCA can lead to superior improvements in cardiac function, clinical outcomes, and serum biomarkers at a 6-month follow-up.

Timeline

Start
2022-12-31
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Background Metoprolol Other / unclassified 25 mg —
Background Spironolactone Small molecule 20 mg —
Background sacubitril/valsartan Unknown 50 mg —